Rifampin interacts with HIV therapy by inducing hepatic enzymes, leading to reduced antiretroviral drug levels. Which management option helps mitigate this interaction?

• A. Use rifabutin instead of rifampin
• B. Double the antiretroviral therapy dose
• C. Add an additional antiretroviral drug
• D. Stop HIV therapy during TB treatment

Answer: (A)

Rifampin triggers strong hepatic enzyme induction, which lowers the levels of many antiretrovirals and can compromise HIV control. Substituting rifampin with rifabutin is the best way to mitigate this interaction because rifabutin induces these enzymes much less, so antiretroviral levels are better preserved while still treating TB.

In practice, this substitution is accompanied by appropriate dose adjustments and monitoring, especially if the patient’s ART includes boosted protease inhibitors or certain non-nucleoside reverse transcriptase inhibitors, to avoid further toxicity or insufficient drug exposure. Other options—significantly increasing ART doses or adding drugs to overcome the interaction, or stopping HIV therapy—do not address the pharmacokinetic clash and carry greater risk or harm.